title: Pharmacokinetics of sarizotan after oral administration of single and repeat doses in healthy subjects.
abstract: OBJECTIVE
  Sarizotan is a 5-HTIA receptor agonist with high affinity for D3 and D4 receptors. Here we report the pharmacokinetic and tolerability results from four Phase 1 studies.
  
  
  METHODS
  Two single-dose (5 -25 mg, n = 25, 0.5 - 5 mg, n = 16) and two multiple-dose (10 and 20 mg b.i.d., n = 30, 5 mg b.i.d., n = 12) studies with orally administered sarizotan HCl were carried out in healthy subjects.
  
  
  METHODS
  Plasma sarizotan HCl concentrations were measured using a validated HPLC method and fluorescence or MS/MS detection. Pharmacokinetic parameters were obtained using standard non-compartmental methods.
  
  
  RESULTS
  Sarizotan was rapidly absorbed, group-median times to reach maximum concentration (tmax) ranged from 0.5 -2.25 h after single doses and during steady state. Maximum plasma concentration (Cmax) and tmax were slightly dependent on formulation and food intake, whereas area under the curve (AUC) was unaffected by these factors. AUC and Cmax increased dose-proportionally over the tested dose range. Independently of dose and time, sarizotan HCl plasma concentrations declined polyexponentially with a terminal elimination half-life (t1/2) of 5 - 7 h. Accumulation factors corresponded to t1/2 values, and steady state was reached within 24 h. Plasma metabolite concentrations were considerably lower than those of the parent drug. The ratio metabolite AUC : parent drug AUC was time- and dose-independent for all three metabolites suggesting that the metabolism of sarizotan is non-saturable in the tested dose range.
  
  
  CONCLUSIONS
  The pharmacokinetics of sarizotan were dose-proportional and time-independent for the dose range 0.5 -25 mg). The drug was well-tolerated by healthy subjects up to a single dose of 20 mg.
authors.affiliation: Department of Clinical Pharmacology and Pharmacokinetics, Merck KGaA, Darmstadt, Germany. Sonja.Kroesser@merck.de
authors.forename: S
authors.initials: S
authors.lastname: Krösser
authors.forename: J
authors.initials: J
authors.lastname: Tillner
authors.forename: M
authors.initials: M
authors.lastname: Fluck
authors.forename: W
authors.initials: W
authors.lastname: Ungethüm
authors.forename: P
authors.initials: P
authors.lastname: Wolna
authors.forename: A
authors.initials: A
authors.lastname: Kovar
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D019540:Area Under Curve; D002851:Chromatography, High Pressure Liquid; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D018565:Food-Drug Interactions; D006207:Half-Life; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D008875:Middle Aged; D009930:Organic Chemicals / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*
chemical_list: D000978:Antiparkinson Agents; D009930:Organic Chemicals; D017366:Serotonin Receptor Agonists; C443959:sarizotan